Press release
Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24. Dr. Robert Frantz, Director of the Pulmonary Hypertension Clinic and Professor of Medicine at Mayo Clinic will present the data on behalf of the TORREY Study investigators.\n\n\nSession and Poster Details\n\n\nSession Title: Breaking News: 2023 Clinical Trial Results in Pulmonary Medicine\nDate and Time: Monday, May 22, 2023, 9:04 AM EDT\nSession Location: Walter E. Washington Convention Center, Ballroom C (Level 3)\nPresentation Title: Seralutinib Treatment in Adult Subjects with Pulmonary Arterial Hypertension: Results from the TORREY Study\nPresenting Author: Robert Frantz, M.D.\n\n\nSession Title: Poster Discussion Session. D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE\nDate and Time: Wednesday, May 24, 2023, 12:00 PM EDT\nSession Location: Walter E. Washington Convention Center, Room 151 A (Street Level)\nPoster Title: 401 - Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial\nPresenting Author: Robert Frantz, M.D.\n\n\nThe presentation and poster will also be made available in the “Posters and Publications” section of the Gossamer Bio website at gossamerbio.com.\n\n\nFollowing the positive results observed in the TORREY study and discussions with worldwide regulatory authorities, Gossamer plans to initiate a registrational Phase 3 clinical trial in patients with PAH in the third quarter of 2023.\n\n\nAbout Gossamer Bio\n\n\nGossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.\n\n\nForward-Looking Statements\n\n\nGossamer cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking s...